Filkri Purple Book BLA 761027

BLA number
761027
Proprietary names
Filkri
Proper names
filgrastim-laha
Applicant
Accord BioPharma Inc.
Center
CDER
First observed release
2026-06-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Filkrifilgrastim-laha351(k) Biosimilar300MCG/0.5MLInjectionIntravenous, SubcutaneousPre-Filled SyringeRxLicensed2026-01-15
002Filkrifilgrastim-laha351(k) Biosimilar480MCG/0.8MLInjectionIntravenous, SubcutaneousPre-Filled SyringeRxLicensed2026-01-15

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
103353Neupogenfilgrastim351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-06-01N001Filkri351(k) BiosimilarRxAccord BioPharma Inc.
2026-06-01N002Filkri351(k) BiosimilarRxAccord BioPharma Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2026-06-01001Filkri351(k) BiosimilarRxLicensed2026-01-15
2026-06-01002Filkri351(k) BiosimilarRxLicensed2026-01-15